Menu
← Oncology Approval Tracker
FDA DECISION ·
Margenza + chemotherapy
margetuximab-cmkb + chemotherapy · MacroGenics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic HER2-positive breast cancer after at least two HER2-directed regimens, at least one in the metastatic setting.
LAMPGEN ANALYSIS
Why it matters
Added a HER2-directed antibody combined with chemotherapy after prior HER2 treatment.
What research teams should watch
Confirm prior regimen setting, and plan infusion reaction and cardiac monitoring.
PRIMARY RECORDS